Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6644815 | 0.85 | LMNA (0.38) | LMNATHRBNPC1RAB9AKMT2A | |
| SCHEMBL6648464 | 0.84 | POLB (0.42) | LMNATHRBKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL23620907 | 0.83 | SSTR4 (0.34) | RAB9AKDM4ECSNK2A2CSNK2A1 | |
| SCHEMBL29392374 | 0.83 | SSTR4 (0.34) | RAB9AKDM4ECSNK2A2CSNK2A1 | |
| SCHEMBL19674226 | 0.79 | AOC3 (0.34) | RAB9AKDM4E | |
| SCHEMBL30648808 | 0.79 | PHLPP2 (0.36) | ALDH1A1CSNK2A2CSNK2A1 | |
| SCHEMBL26640862 | 0.79 | PHLPP2 (0.36) | ALDH1A1CSNK2A2CSNK2A1 | |
| SCHEMBL18519393 | 0.78 | CSNK2A1 (0.35) | LMNARAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL20576747 | 0.76 | LMNA (0.33) | LMNATHRBNPC1RAB9AKMT2A | |
| SCHEMBL6647719 | 0.76 | F2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | LMNA 1410/4885THRB 340/4885NPC1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.